» Articles » PMID: 29957299

Depression and Survival of Glioma Patients: A Systematic Review and Meta-analysis

Overview
Publisher Elsevier
Specialty Neurology
Date 2018 Jun 30
PMID 29957299
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: There is currently a lack of a well-formed consensus regarding the effects of depression on the survival of glioma patients. A more thorough understanding of such effects may better highlight the importance of recognizing depressive symptoms in this patient population and guide treatment plans in the future.

Objective: The aim of this meta-analysis was to study the effect of depression on glioma patients' survival.

Methods: A meta-analysis was conducted according to the PRISMA guidelines. PubMed, Embase, and Cochrane databases were searched for studies that reported depression and survival among glioma patients through 11/06/2016. Both random-effects (RE) and fixed-effect (FE) models were used to compare survival outcomes in glioma patients with and without depression.

Results: Out of 619 identified articles, six were selected for the meta-analysis. Using RE model, the various measures for survival outcomes displayed worsened outcomes for both high and low-grade glioma patients with depression compared to those without depression. For binary survival outcomes, the overall pooled risk ratio for survival was 0.70 (95% CI: 0.47, 1.04; 6 studies; I = 54.9%, P-heterogeneity = 0.05) for high grade gliomas (HGG) and 0.28 (95% CI: 0.04, 1.78; I = 0%, P-heterogeneity = 1.00; one study) for low grade gliomas (LGG) was. A sub-group analysis in the HGG group by depression timing (pre- versus post-operative) revealed no differences between depression and survival outcomes (P-interaction = 0.47). For continuous survival outcomes, no statistically significant difference was found among the high and low-grade glioma groups (P-interaction = 0.31). The standardized mean difference (SMD) in survival outcomes was -0.56 months (95%CI: -1.13, 0.02; 4 studies, I = 89.4%, P-heterogeneity < 0.01) for HGG and -1.69 months (95%CI: -3.26, -0.13; one study; I = 0%, P-heterogeneity = 1.00) for LGG. In patients with HGG, the pooled HR of death also showed a borderline significant increased risk of death among depressive patients (HR 1.42, 95% CI: 1.00, 2.01). Results using the FE model were not materially different.

Conclusions: Depression was associated with significantly worsened survival regardless of time of diagnosis, especially among patients with high-grade glioma.

Citing Articles

Preoperative Peripheral Blood Serotonin and Kynurenine Levels Are Associated With Oncological Outcomes in Glioblastoma IDH-wt Patients.

Snider S, Gagliardi F, De Domenico P, Comai S, Bertazzo A, Nasini S Int J Tryptophan Res. 2025; 18:11786469241312475.

PMID: 39959303 PMC: 11826855. DOI: 10.1177/11786469241312475.


Baseline factors relating to depressive symptoms at one year postoperative in patients with diffuse glioma.

Belgers V, Tolver A, Klein M, Douw L, Niers J, Piil K Neurooncol Pract. 2025; 12(1):122-130.

PMID: 39917762 PMC: 11798611. DOI: 10.1093/nop/npae085.


Impact of antidepressant use on survival outcomes in glioma patients: A systematic review and meta-analysis.

Ge Y, Cao Y, Wang Q, Wang Y, Ma W Neurooncol Adv. 2024; 6(1):vdae181.

PMID: 39582812 PMC: 11582889. DOI: 10.1093/noajnl/vdae181.


The effect of depression and anxiety on survival in patients with glioma: a systematic review and meta-analysis.

Dong J, Chen Q, Weng S, Liu L, Wang J, Fang S J Neurooncol. 2024; 170(2):265-275.

PMID: 39225956 DOI: 10.1007/s11060-024-04799-9.


Antidepressant drugs and risk of developing glioma: a national registry-based case-control study and a meta-analysis.

Malmberg C, Numan Hellquist B, Sadanandan S, Sandstrom M, Wu W, Bjorkblom B Am J Epidemiol. 2024; 193(11):1592-1599.

PMID: 38825331 PMC: 11538564. DOI: 10.1093/aje/kwae100.